Menu

Europe Favors “Mission-Oriented” Research in €100B Budget Proposal

The plan would also allow non-EU countries to pay to participate in EU research programs, albeit without wielding “decisional power.”

Jun 11, 2018
Catherine Offord

ISTOCK, ARTJAZZThe European Commission has outlined how it intends to divvy up €100 billion (about $120 billion USD) in research funding from 2021 to 2027. In documents published earlier last week (June 7), European policymakers laid out plans to dedicate a large slab to supporting research “focused around missions,” and to allow other countries, such as a post-Brexit Britain, to pay to take part in EU research programs.

Around €10 billion from the budget will be used for the new European Innovation Council, which has been set up to help to smooth the passage of basic research and technology from the lab to the marketplace. More than half of the overall budget is dedicated to what the proposal terms a “mission-oriented approach,” in which funding is allocated on the basis of desired outcome rather than research area. The outcomes are divided into five categories: health, inclusive and secure society, digital and industry, climate, energy and mobility, and food and natural resources.

See “European Commission Recommends €100 Billion for Research

Some policymakers view the new mission-driven approach as a way to make research more relevant to the public. In a statement, European Commissioner for Research, Science and Innovation Carlos Moedas says that “instead of saying that we will map the brain, we can say that our mission is to cure some diseases like Alzheimer’s or dementia, or that we’ll do something for people not to die of cancer, and people will understand better what we do.”

But others are concerned that the new focus may overlook important, curiosity-driven research and risks overselling the probability of these projects’ success. “You can’t just say we put a couple of million into a funding programme and we will arrive there,” Thomas Estermann, director for governance, funding, and public policy development at the European University Association, tells Times Higher Education.

Meanwhile, the European Research Council (ERC), a major funder of basic research across the continent, has had its funds only slightly raised, from €13.1 billion to €16.6 billion—a move that has disappointed some researchers who were expecting far more. Speaking to Science, Kurt Deketelaere, secretary-general of the League of European Research Universities, says that university representatives “will fight for a better distribution of the budget.”

Another, much-anticipated element of the plan is the window it opens for non-EU countries to opt in to its science programs. In a more detailed document, the Commission explains how any other country may pay to take part in European research, provided it fits certain criteria including a “commitment to a rules-based open market economy” and having “a good capacity in science.”

See “Scientists Concerned About Future of International Collaboration

However, at least one part of this document is likely to receive disapproval from the U.K., which is scheduled to leave the E.U. in early 2019 and is keen to maintain influence over European research projects in return for continued financial contributions. The new proposal states that any agreement with a non-EU member will “not confer to the third country a decisional power on the programme.”

The proposal will have to undergo several rounds of negotiations before it can be approved by European Parliament.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.